MY168784A - The new stable polyethylene glycol conjugate of interferon alpha,represented by one positional isomer - Google Patents
The new stable polyethylene glycol conjugate of interferon alpha,represented by one positional isomerInfo
- Publication number
- MY168784A MY168784A MYPI2013000216A MYPI2013000216A MY168784A MY 168784 A MY168784 A MY 168784A MY PI2013000216 A MYPI2013000216 A MY PI2013000216A MY PI2013000216 A MYPI2013000216 A MY PI2013000216A MY 168784 A MY168784 A MY 168784A
- Authority
- MY
- Malaysia
- Prior art keywords
- conjugate
- formula
- ifn
- peg
- interferon
- Prior art date
Links
- 108010047761 Interferon-alpha Proteins 0.000 title abstract 2
- 102000006992 Interferon-alpha Human genes 0.000 title abstract 2
- 239000002202 Polyethylene glycol Substances 0.000 title abstract 2
- 229920001223 polyethylene glycol Polymers 0.000 title abstract 2
- 208000031951 Primary immunodeficiency Diseases 0.000 abstract 2
- 206010054979 Secondary immunodeficiency Diseases 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 230000000694 effects Effects 0.000 abstract 2
- 229940079322 interferon Drugs 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 101000959820 Homo sapiens Interferon alpha-1/13 Proteins 0.000 abstract 1
- 102100040019 Interferon alpha-1/13 Human genes 0.000 abstract 1
- 108010050904 Interferons Proteins 0.000 abstract 1
- 102000014150 Interferons Human genes 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 208000036142 Viral infection Diseases 0.000 abstract 1
- 230000001028 anti-proliverative effect Effects 0.000 abstract 1
- 230000000840 anti-viral effect Effects 0.000 abstract 1
- 230000004071 biological effect Effects 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000002519 immonomodulatory effect Effects 0.000 abstract 1
- 230000005847 immunogenicity Effects 0.000 abstract 1
- 229940126601 medicinal product Drugs 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- 229920001184 polypeptide Polymers 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 230000002035 prolonged effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/555—Interferons [IFN]
- C07K14/56—IFN-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Virology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Communicable Diseases (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Hematology (AREA)
- Biotechnology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
THE INVENTION IS RELATED TO THE PHARMACEUTICAL INDUSTRY AND MEDICINE, IN PARTICULAR, TO NEW PEG-INTERFERON DERIVATIVES AND THE DISCOVERY OF A NEW FUNCTIONALLY ACTIVE, HIGHLY STABLE CONJUGATE OF INTERFERON TO POLYETHYLENE GLYCOL WITH AN ACTIVITY OF INTERFERON ALPHA, WITH REDUCED IMMUNOGENICITY, WITH PROLONGED BIOLOGICAL EFFECTS AND IMPROVED PHARMACOKINETIC PARAMETERS OF GENERAL FORMULA: WHERE: N - INTEGRAL VALUES FROM 227 TO 10 000, SO THAT THE MOLECULAR WEIGHT OF PEG IS ABOUT 10 000-40 000 DA; M - INTEGER ? 4; IFN- NATURAL OR RECOMBINANT POLYPEPTIDE HAVING THE ACTIVITY OF IFN-ALPHA. ALSO, THE INVENTION IS RELATED TO DRUGS CONTAINING THE DECLARED CONJUGATE OF THE FORMULA (I), PHARMACEUTICAL COMPOSITIONS CONTAINING PEG-IFN CONJUGATE AND THERAPEUTICALLY ACCEPTABLE EXCIPIENTS SUITABLE FOR TREATMENT OF VIRAL INFECTIONS AND CANCER, AS WELL AS DISEASES ASSOCIATED WITH PRIMARY OR SECONDARY IMMUNODEFICIENCY. THE INVENTION IS RELATED TO THE USE OF CONJUGATE OF FORMULA (I) IN MEDICINAL PRODUCTS, WHICH HAVE ANTIVIRAL, ANTIPROLIFERATIVE AND IMMUNOMODULATORY ACTIVITY, TO APPROACHES FOR PREVENTION AND / OR TREATMENT OF DISEASES ASSOCIATED WITH PRIMARY OR SECONDARY IMMUNODEFICIENCY THAT INCLUDE ADMINISTRATION OF THERAPEUTICALLY EFFECTIVE AMOUNT OF CONJUGATE OF FORMULA (I), AND TO THE CONTAINER WITH SUCH PHARMACEUTICAL COMPOSITION.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| RU2010129824/10A RU2447083C1 (en) | 2010-07-20 | 2010-07-20 | NOVEL FUNCTIONALLY ACTIVE, HIGHLY PURE, STABLE CONJUGATE OF INTERFERON α WITH POLYETHYLENE GLYCOL, REPRESENTED BY ONE PEG- NαH-IFN POSITIONAL ISOMER, WITH IMPROVED IMMUNOGENICITY, WITH PROLONGED BIOLOGICAL ACTION, SUITABLE FOR MEDICAL APPLICATION, AND IMMUNOLOGICAL AGENT BASED THEREON |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MY168784A true MY168784A (en) | 2018-12-04 |
Family
ID=45497062
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MYPI2013000216A MY168784A (en) | 2010-07-20 | 2010-09-24 | The new stable polyethylene glycol conjugate of interferon alpha,represented by one positional isomer |
Country Status (20)
| Country | Link |
|---|---|
| KR (1) | KR101586372B1 (en) |
| CN (1) | CN102617736B (en) |
| AR (1) | AR087227A1 (en) |
| BR (1) | BRPI1101565A2 (en) |
| CO (1) | CO6680611A2 (en) |
| CR (1) | CR20130021A (en) |
| CU (1) | CU24193B1 (en) |
| DO (1) | DOP2013000002A (en) |
| EA (1) | EA020257B1 (en) |
| EC (1) | ECSP13012398A (en) |
| MX (1) | MX2011007458A (en) |
| MY (1) | MY168784A (en) |
| NI (1) | NI201300008A (en) |
| PE (1) | PE20131034A1 (en) |
| PH (1) | PH12012502425A1 (en) |
| RU (1) | RU2447083C1 (en) |
| SG (1) | SG187117A1 (en) |
| UA (1) | UA99766C2 (en) |
| UY (1) | UY33525A (en) |
| WO (1) | WO2012011836A1 (en) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2515913C1 (en) * | 2013-03-22 | 2014-05-20 | Федеральное государственное унитарное предприятие "Государственный научно-исследовательский институт генетики и селекции промышленных микроорганизмов" (ФГУП "ГосНИИгенетика") | HYBRID PROTEIN HAVING PROLONGED ACTION, BASED ON RECOMBINANT HUMAN INTERFERON ALPHA-2 (VARIANTS), METHOD OF ITS PRODUCTION AND STRAIN OF Saccharomyces cerevisiae FOR IMPLEMENTING THIS METHOD (VERSIONS) |
| EA021643B1 (en) * | 2013-03-28 | 2015-07-30 | Илья Александрович МАРКОВ | Monopegylated interferon-alpha of linear structure and a pharmaceutical composition for preparing a medicament having interferon-alpha activity |
| EA021610B1 (en) * | 2013-03-28 | 2015-07-30 | Илья Александрович МАРКОВ | Liquid antiviral formulation |
| CN103463623B (en) * | 2013-09-03 | 2015-09-09 | 长春海伯尔生物技术有限责任公司 | A kind of Peg-IFN alpha-2b injection and preparation method thereof |
| RU2554761C1 (en) * | 2014-05-13 | 2015-06-27 | Закрытое акционерное общество "Сибирский центр фармакологии и биотехнологии" | Anti-enteroviral and immunostimulating agent |
| RU2572800C1 (en) * | 2014-09-22 | 2016-01-20 | Закрытое Акционерное Общество "Биокад" | New formulation containing polyethylene glycol (peg) conjugated interferon alpha-2beta characterised by less painful administration |
| EA029498B1 (en) * | 2015-11-24 | 2018-04-30 | Учреждение Белорусского государственного университета "Научно-исследовательский институт физико-химических проблем" (НИИ ФХП БГУ) | ANTI-TUMOUR DRUG BASED ON RECOMBINANT INTERFERON ALPHA-2b IN THE FORM OF MICROPARTICLES FOR PARENTERAL ADMINISTRATION |
| RU2678332C1 (en) | 2017-09-08 | 2019-01-28 | Общество с ограниченной ответственностью "Саентифик Фьючер Менеджмент" (ООО "СФМ") | Pegylated interferon lambda with high bioaccessability in oral use and method for production thereof |
| WO2021212220A1 (en) * | 2020-04-20 | 2021-10-28 | Altum Pharmaceuticals Inc. | Recombinant interferon |
| CN114392237B (en) * | 2021-12-28 | 2024-02-02 | 上海允英生物医药科技有限公司 | Freeze-dried virus preparation and preparation method thereof |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5951974A (en) * | 1993-11-10 | 1999-09-14 | Enzon, Inc. | Interferon polymer conjugates |
| US20030053982A1 (en) * | 1994-09-26 | 2003-03-20 | Kinstler Olaf B. | N-terminally chemically modified protein compositions and methods |
| TW426523B (en) * | 1995-04-06 | 2001-03-21 | Hoffmann La Roche | Interferon solution |
| TW517067B (en) * | 1996-05-31 | 2003-01-11 | Hoffmann La Roche | Interferon conjugates |
| EA200500475A1 (en) * | 2002-09-09 | 2005-10-27 | Нектар Терапеутикс Ал, Корпорейшн | WATER-SOLUBLE POLYMERIC ALCANALS |
| RU2311930C2 (en) * | 2004-04-30 | 2007-12-10 | Закрытое акционерное общество "ВЕРОФАРМ" | Pagylated interferon against viral infection |
| AU2005260664A1 (en) * | 2004-06-30 | 2006-01-12 | Egen Corporation | Pegylated interferon alpha-1b |
| CA2614987C (en) * | 2005-07-19 | 2013-10-08 | Nektar Therapeutics Al, Corporation | Method for preparing polymer maleimides |
| EP2044097A4 (en) * | 2006-06-23 | 2010-10-06 | Quintessence Biosciences Inc | MODIFIED RIBONUCLEASES |
| CN101491682A (en) * | 2008-04-30 | 2009-07-29 | 北京凯正生物工程发展有限责任公司 | PEG-IFN omega conjugate and preparation technique thereof |
| CN101591387A (en) * | 2008-05-28 | 2009-12-02 | 中国人民解放军军事医学科学院微生物流行病研究所 | Pegylated recombinant human interferon omega conjugate |
| CN101514229B (en) * | 2009-04-03 | 2012-05-09 | 海南四环心脑血管药物研究院有限公司 | Human interferon alpha derivative and polyethylene glycol modified substance thereof |
-
2010
- 2010-07-20 RU RU2010129824/10A patent/RU2447083C1/en active
- 2010-09-24 KR KR1020137001858A patent/KR101586372B1/en not_active Expired - Fee Related
- 2010-09-24 PE PE2013000084A patent/PE20131034A1/en not_active Application Discontinuation
- 2010-09-24 WO PCT/RU2010/000529 patent/WO2012011836A1/en not_active Ceased
- 2010-09-24 CU CUP2013000013A patent/CU24193B1/en active IP Right Grant
- 2010-09-24 SG SG2013003801A patent/SG187117A1/en unknown
- 2010-09-24 PH PH1/2012/502425A patent/PH12012502425A1/en unknown
- 2010-09-24 MY MYPI2013000216A patent/MY168784A/en unknown
- 2010-12-15 UA UAA201015114A patent/UA99766C2/en unknown
-
2011
- 2011-04-01 BR BRPI1101565-9A patent/BRPI1101565A2/en not_active IP Right Cessation
- 2011-06-21 EA EA201100809A patent/EA020257B1/en not_active IP Right Cessation
- 2011-07-12 MX MX2011007458A patent/MX2011007458A/en active IP Right Grant
- 2011-07-19 CN CN201110214149.6A patent/CN102617736B/en not_active Expired - Fee Related
- 2011-07-19 AR ARP110102606A patent/AR087227A1/en unknown
- 2011-07-20 UY UY0001033525A patent/UY33525A/en unknown
-
2013
- 2013-01-04 DO DO2013000002A patent/DOP2013000002A/en unknown
- 2013-01-18 CO CO13009157A patent/CO6680611A2/en unknown
- 2013-01-18 CR CR20130021A patent/CR20130021A/en unknown
- 2013-01-18 NI NI201300008A patent/NI201300008A/en unknown
- 2013-01-18 EC ECSP13012398 patent/ECSP13012398A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| NI201300008A (en) | 2014-05-26 |
| KR101586372B1 (en) | 2016-01-18 |
| SG187117A1 (en) | 2013-02-28 |
| AR087227A1 (en) | 2014-03-12 |
| UY33525A (en) | 2012-02-29 |
| UA99766C2 (en) | 2012-09-25 |
| CU20130013A7 (en) | 2013-04-19 |
| HK1170504A1 (en) | 2013-03-01 |
| CO6680611A2 (en) | 2013-05-31 |
| RU2010129824A (en) | 2012-01-27 |
| WO2012011836A1 (en) | 2012-01-26 |
| CU24193B1 (en) | 2016-09-30 |
| EA020257B1 (en) | 2014-09-30 |
| PH12012502425A1 (en) | 2013-07-08 |
| CR20130021A (en) | 2013-02-20 |
| EA201100809A1 (en) | 2012-01-30 |
| DOP2013000002A (en) | 2013-09-15 |
| ECSP13012398A (en) | 2013-05-31 |
| CN102617736B (en) | 2015-11-25 |
| BRPI1101565A2 (en) | 2012-12-04 |
| RU2447083C1 (en) | 2012-04-10 |
| MX2011007458A (en) | 2012-01-19 |
| KR20130056885A (en) | 2013-05-30 |
| PE20131034A1 (en) | 2013-09-27 |
| CN102617736A (en) | 2012-08-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MY168784A (en) | The new stable polyethylene glycol conjugate of interferon alpha,represented by one positional isomer | |
| US10544193B2 (en) | Compositions and methods for treating diseases by inhibiting exosome release | |
| MX2012007410A (en) | Novel antiviral compounds. | |
| BR112022010574A2 (en) | PHARMACEUTICAL COMPOSITIONS INCLUDING CABOTEGRAVIR | |
| EA201171376A1 (en) | THYENO DERIVATIVES [2,3-B] PIRIDINE AS VIRUS REPLICATION INHIBITORS | |
| MX2017004592A (en) | Pharmaceutical formulations for the oral delivery of peptide or protein drugs. | |
| EA201290395A1 (en) | IMMUNOMODULATING POLYPEPTIDES OBTAINED FROM IL-2 AND THEIR USE FOR THE TREATMENT OF CANCER AND CHRONIC INFECTIONS | |
| PH12012502426A1 (en) | A novel conjugate of granulocyte colony-stimulating factor(g-csf) with polyethylene glycol | |
| US11559567B2 (en) | Dosage regimen for pegylated interferon | |
| MX2023001572A (en) | Solid dosage forms of palbociclib. | |
| CR20220053A (en) | DRUG DELIVERY SYSTEM FOR THE ADMINISTRATION OF ANTIVIRAL AGENTS | |
| KR20070012522A (en) | Treatment and prevention of respiratory viral infections with immunomodulatory compounds | |
| D Micewicz et al. | Inhibitors of HIV-1 entry | |
| PH12022551985A1 (en) | Compositions and methods for delivering pharmaceutically active agents | |
| TH133837A (en) | ||
| WO2022229459A1 (en) | Compound for treating covid-19 infections | |
| Nelson et al. | Effect of faldaprevir on atazanavir pharmacokinetics in patients with HIV/HCV co-infection | |
| RU2014116988A (en) | ALISPORIVIR FOR TREATING INFECTIONS CAUSED BY HEPATITIS C VIRUS | |
| RU2014140049A (en) | MOLECULE interferon-β-1a HUMAN pegylated, possess antiviral, immunomodulating and antiproliferative activity, with improved stability, reduced immunogenicity, improved pharmacokinetic and pharmacodynamic parameters suitable for medical applications, and immunobiological BEING ON ITS BASIS | |
| RU2012109938A (en) | METHOD FOR TREATING VIRAL HEPATITIS C | |
| RU2013158037A (en) | MOLECULE interferon-β-1a HUMAN pegylated, possess antiviral, immunomodulating and antiproliferative activity, with improved stability, reduced immunogenicity, improved pharmacokinetic and pharmacodynamic parameters suitable for medical applications, and immunobiological BEING ON ITS BASIS | |
| NZ746125A (en) | Pharmaceutical compositions comprising an anti-retroviral drug and a pharmacokinetic enhancer |